|
Aminoglutethimide
May decrease dexamethasone-induced adrenal suppression.
Amphotericin B
Cardiac enlargement and CHF have been reported.
Anticholinesterases
May antagonize anticholinesterase effects in myasthenia gravis.
Anticoagulants, oral
May alter anticoagulant dose requirements.
Antidiabetic agents
Dexamethasone may increase blood glucose levels, necessitating antidiabetic agent dosage adjustments.
Aprepitant
Dexamethasone plasma levels may be elevated and the t ½ prolonged, increasing the pharmacologic effects and adverse reactions.
Cholestyramine, epinephrine
Dexamethasone plasma levels may be reduced, decreasing the efficacy.
Cyclosporine
Activity of both cyclosporine and dexamethasone may be increased. In addition, convulsions have been reported.
CYP3A4 substrates (eg, erythromycin, indinavir)
Plasma levels may be reduced by dexamethasone, decreasing efficacy.
Digoxin
Because of possible dexamethasone-induced hypokalemia, the risk of arrhythmias may be increased.
Hepatic enzyme inducers (eg, barbiturates, carbamazepine, phenytoin, rifampin)
Dexamethasone plasma levels may be reduced, decreasing the efficacy. In addition, seizure control with phenytoin may be altered.
Hepatic enzyme inhibitors (eg, azole antifungal agents [eg, ketoconazole], estrogens [including oral contraceptives], macrolide antibiotics [eg, erythromycin])
Dexamethasone plasma levels may be elevated, increasing the pharmacologic effects and adverse reactions. In addition, ketoconazole can inhibit adrenal corticosteroid synthesis, causing adrenal insufficiency during dexamethasone withdrawal.
NSAIDs, salicylates
Risk of GI adverse reactions may be increased. In addition, salicylate levels and efficacy may be reduced.
Potassium-depleting agents (eg, amphotericin B, loop and thiazide diuretics)
Risk of hypokalemia may be increased.
Thalidomide
Use with caution, toxic epidermal necrolysis has been reported with concurrent use of dexamethasone.
|
